Blood group-related antigens constitute a family of carbohydrate structures carried on both glycoproteins and glycolipids of cell membranes (Hakomori & Kannagi, 1983; Feizi, 1985; Coon & Weinstein, 1986; Lloyd, 1987) . These antigens, first described on erythrocytes, have been demonstrated in many extraerythroid normal tissues (Coon & Weinstein, 1986) and in a variety of human tumours (Feizi, 1985; Lloyd, 1987) . Among these blood group antigens, H and Y determinants have been the subject of a number of investigations as to their distribution in normal and malignant epithelial cells (Szulman, 1962; Coon & Weinstein, 1986; Kimmel et al., 1986; Vowden et al., 1986; Schoetag et al., 1987; Le Pendu et al., 1989; Orntoft et al., 1989) . H and Y determinant expression may be related to invasive potential of urothelial carcinomas (Coon & Weinstein, 1986; Orntoft et al., 1989) . H and Y antigens are also present on platelets but their appearance on lymphoid cells remains controversial (Lloyd, 1987; Mollicone et al., 1988; Dunstan, 1986) and their expression by malignant lymphomas, to our knowledge, has never been documented.
As a part of our search for monoclonal antibodies that react with routinely fixed and embedded tissues, we obtained two monoclonal antibodies -BNH9 and BNF13 -directed against blood group related H and Y determinants (Blancher et al., 1988) . The reactivity of these monoclonal antibodies (MoAbs) with normal epithelium and malignancies of epithelial origin was not surprising, but strong labelling of cells in anaplastic large cell (ALC) (Ki-I lymphoma) lymphomas (Stein et al., 1985; Delsol et al., 1988) during the initial screening, was thought both unusual and promising. The study was therefore systematised to include as many cases as possible from our files of non-Hodgkin's lymphomas (NHL) including ALC lymphomas and Hodgkin's disease (HD), with simultaneous assessment of the expression of these antigens by normal, reactive and activated lymphocytes.
Materials and methods
Production of antibodies BNH9 and BNF13 MoAbs were generated by using splenocytes from nude mice grafted with a human lung adenocarCorrespondence: G. Delsol (Al Saati et al., 1987) . Non-immunoglobulin producing myeloma cell line P3 x 63-Ag8-653 was used as fusion partner. Fusions were performed using standard techniques (Kohler & Milstein, 1976) . When hybridoma growth could be detected, supernatants were tested for antibody-binding activity by immunohistochemistry on frozen sections of the BUR tumour and human tonsils (Al Saati et al., 1987; 1989b) . Positive supernatants were further tested on paraffin sections to detect MoAbs directed against fixativeresistant antigens. BNH9 and BNF13 were selected because of their reactivity on paraffin sections. Provisional data on BNH9 (IgM) and BNF13 (?IgM/IgG2a) MoAbs was reported previously (Blancher et al., 1988) . Immunoprecipitation showed that BNH9 detected two bands: one of 150 kD and a second weak band of 120 kD, while BNF13 produced three bands: two of 120 kD and 130 kD and one weak band of 150 kD.
Characterisation of antigens BNF13 antibody was submitted to the First International Workshop on monoclonal antibodies against human red blood cell and related antigens (Blancher et al., 1988; Oriol et al., 1987) . Further investigation showed that this antibody reacts strongly with H type 2 antigen as well as with Y type 2 and type 2 precursor (Oriol et al., 1987) . In a preliminary study, BNH9 antibody was studied by haemagglutination assays using red blood cells of various phenotypes. The specificities of BNH9 and BNF13 Mobs against glycoconjugates were analysed by inhibition of agglutination after incubation with well defined synthetic oligosaccharides (Lemieux, 1978; Oriol et al., 1987) bound to an inorganic carrier (crystalline silica) (Synsorb Chembiomed, Edmonton, Canada).
Immunoenzymatic staining
A previously described three-stage immunoperoxidase procedure was used . Briefly, after incubation with undiluted supernatants, sections were incubated in turn with peroxidase-conjugated rabbit anti-mouse Ig (Dakopatts, Copenhagen, Denmark) and with peroxidase-conjugated swine anti-rabbit Ig (Dakopatts) both diluted at 1:15 in phosphate buffered saline (PBS). Peroxidase activity was revealed by diaminobenzidine tetrahydrochloride (DAB) (Sigma, New Jersey, USA). Tissue samples were fixed mostly in ethanol-based Bouin's (Dubosq-Brazil) fluid or BouinHolland, but a few were fixed in B5 or 10% formalin, to assess the fixative-dependence of the staining intensity. A prior trypsination step was used for paraffin sections. In the study of lymphoid tumours, negative controls were used by the omission of BNH9 and BNF1 3 MoAbs or by their replacement with a non-relevant MoAb such as KL1; an anticytokeratin antibody (Immunotech, Marseille, France). Detailed immunophenotype of malignant lymphomas in our files was known because of the use of a broad panel of MoAbs directed against B-cell, T-cell, macrophage and activation associated antigens, and has been the subject of previous reports (Al Saati et al., 1984; Delsol et al., 1988) . Staining of erythrocytes and blood-vessel endothelium served as positive controls.
Reactivities with activated peripheral blood lymphocytes, normal lymphoid tissues, and malignant lymphomas Peripheral blood mononuclear cells from five healthy volunteers were stimulated with 1% PHA (Difco Lab) for 3 days.
PHA-stimulated cells were tested for reactivity with BNH9 and BNF13 MoAbs on day 0, 1, 2 and 3, using the alkaline phosphatase: anti-alkaline phosphatase (APAAP) technique (Cordell et al., 1984) . In order to know whether antigens detected by these antibodies were of the activation type inducible by EBV (Calender et al., 1987) , five EBV-positive lymphoblastoid cell lines from own laboratory were tested by staining with the APAAP technique.
The reactivities of BNH9 and BNF13 MoAbs were investigated on normal tissues as well as reactive lymph nodes (n = 20) and tonsils (n = 10). In the initial study of the reactivity of these antibodies with malignant lymphomas, we noted an unexpected reactivity of some cases of ALC lymphomas (Ki-I lymphomas) described by Stein et al. (1985; Delsol et al., 1988) . This finding prompted us to systematically investigate a large series of ALC lymphomas (n = 127) as well as NHL of non-anaplastic type (n = 208) and cases of HD of all subtypes (n = 145).
Reactivities with non-lymphoid normal tissues and neoplasms A variety of surgically excised non-lymphoid human tumours from our tissue bank (n = 153) were tested. The reactivities with normal tissues were assessed on paraffin sections using the 'sausage' tissue block method (Battifora, 1986) .
Results

Adsorption with synthetic oligosaccharides
The results of haemagglutination-inhibition with synthetic oligosaccharides and tissue reactivities showed that BNF13 and BNH9 have H-related specificity, but react with different epitopes of the H-antigen. BNF13 was totally adsorbed by H type 2 suggesting binding with an epitope containing the trisaccharide alphaFuc(I-2)BetaGal(I-4)BetaGlcNAc and dependant upon the Beta(I-4)galactosyl linkage. The reactivity of BNH9 MoAb suggested a binding with an epitope containing either the alphaFuc(I-2)BetaGal(I-4)BetaGlcNac or alphaFuc(1-2)BetaGal(I-3)BetaGlcNAc trisaccharide present respectively on H and Y type 2 and H type 1. However, the adsorption by H type 4 could indicate that the reactivity of BNH9 MoAb was dependant on the disaccharide component alphaFuc(1-2)BetaGal present on H type 1, H type 2, H type 4 and Y type 2. These findings were further confirmed by the complete absence of immunostaining of epithelium and blood vessels when absorbed supernatants were tested for their activity on normal human tonsils.
Reactivities with PHA-stimulated lymphocytes and Epstein-Barr Virus (EBV) + lymphoblastoid cell lines Many PHA-transformed lymphocytes showed an extremely weak, diffuse cytoplasmic staining with BNH9 and BNF13
antibodies by the sensitive APAAP procedure. In addition, except for one patient, a small percentage of cells showing a clear membrane staining with both antibodies, emerged on day 3.
All but one EBV + lymphoblastoid cell lines showed 1-3% of cells positive for BNH9 and BNF13 MoAbs. The staining was strong and mainly membrane associated ( Figure  1 ). These cell lines were of polyclonal B-lymphocytes expressing several activation antigens including the Ki-l (CD30) antigen and the recently described CDw7O antigen (Al Saati et al., 1989a) .
Reactivities with normal hematopoietic tissues Immunoperoxidase staining on frozen and paraffin sections gave similar results. On reactive lymph nodes, endothelial cells including post-capillary venules, reacted strongly with both antibodies (Figure 2 ). In addition, stellate reticulum cells of the marginal sinus were also strongly positive for the two MoAbs. By contrast, histiocytes, plasma cells and lymphoid cells including germinal centre cells and immunoblasts in the paracortical area, were consistently negative. In only two reactive lymph nodes, scarce positive small lymphocytelike cells were found. Erythroblasts were considered as possible candidates for this positive reactivity. In normal spleen, only endothelial cells and sinus lining cells were found to be strongly positive. Variation of fixatives did not make a significant difference in the staining patterns. Staining in several randomly chosen bone marrow biopsy specimens was confined to endothelial cells, erythroblasts and a variable number of megakaryocytes. Myeloid cells were unequivocally negative. Reactivities with malignant lymphomas and related disorders Because of the fixation-resistant property of the antigens, only paraffin sections were used in the extended evaluation. However, in the early stages, BNH9 antibody consistently stained more numerous malignant cells than BNF13. Moreover, ten cases which were positive for BNH9 MoAb showed no positive cells with BNF13, while the opposite staining pattern, i.e. BNH9-/BNF13+, was not observed in any case. Thus, the study was mainly focused on the reactivity of BNH9 with paraffin embedded tissue sections from patients with lymphomas and related disease and the results are shown in Tables I, II and III. Anaplastic large cell (ALC) lymphomas (Tables I and II) Tissues in 65 of the 127 cases (51%) reacted with BNH9; while only 25% of these tumours were also positive for BNF13. In a previous report , we had subdivided ALC lymphomas on the basis of the co-expression of Ki-l (CD30) and epithelial membrane antigens (EMA) into three types: Ki-l + /EMA +; Ki-l + /EMAand Ki-l -/EMA + . In the present study, 61/108 cases (56.5%) of Ki-l + /EMA + ALC lymphomas were found to be positive for BNH9. Among tumours expressing either the Ki-l antigen (nine cases) or EMA (ten cases) only one (11%) and three (30%) cases respectively, were positive for BNH9. The number of positive cells varied greatly from case to case but in the majority (40/65) of BNH9 positive cases, 50% to 100% of malignant cells were labelled. There were three cases in which BNH9 stained only 1% of malignant cells. Whatever the number of positive cells, the staining was intense, on the cell membranes, and commonly associated with a dot-like pattern in the paranuclear Golgi area (Figure 3) . No other cells (except the positive control endothelial cells), were stained in BNH9 positive tumours. In addition, it was to noticed that, BNH9 positive ALCs were mainly of either T-cell origin (59%) or null phenotype (31%) ( Table I ). A significant difference was noted in the reactivities of BNH9 with ALC lymphomas in children as compared to those in adults. In (Chittal et al., 1990) . No staining on Reed-Sternberg cells and variants was found in 120 cases; only endothelial cells (used as positive controls), were stained (Figure 4 ). In only 6/126 (4.7%) cases of the other histological types of Hodgkin's disease (nodular sclerosis, mixed cellularity, lymphocyte depletion and unclassified: total = 126 cases), rare morphologically typical Reed-Sternberg cells were found to be positive for BNH9.
Reactivities with non-lymphoid normal tissues and tumours A large panel of normal human tissues obtained from paraffin embedded biopsy specimens (normal multi-tissue block) were stained to specify the reactivities of BNH9 and BNF 13. In all organs, endothelial cells were strongly labelled with the two antibodies. Minor differences were found in the reactivities of BNH9 and BNF1 3 on cells other than endothelial cells. Squamous cells of the skin, tonsil and oesophagus were positive for both antibodies. Sebaceous glands were labelled, in addition to epidermal cells and sweat glands, but only with BNF 13. Varying proportions of glandular structures of the bronchus, gastrointestinal tract, salivary glands and pancreas (except for islets cells) were also stained. A small proportion of tubules in kidney were labelled. Except for the usual reactivity with blood vessels, no significant staining was observed in liver, heart, brain, testis and ovary.
Reactivities of BNH9 and BNF1 3 antibodies with nonlymphoid tumours were assessed on frozen and paraffin sections using the multi-tumour (sausage) tissue block method. Among 153 tested 76 were positive for BNH9. Major positive reactivities were found with carcinomas of the lung (squamous cell: 9/9; adenocarcinoma: 8/9; small cell carcinoma: 3/12), thyroid (7/12), gastrointestinal tract (eosophagus: 1/2; gastric: 6/8; colon: 3/9), pancreas (1/2), liver (1/4), breast (10/11), kidney (1/7), urinary bladder (4/5), prostate (3/5) and uterine cervix (2/2). Soft tissue tumours were negative for BNH9 with the exception of angiosarcoma and synovial sarcoma. Glial tumours and meningiomas were negative. (Oriol et al., 1987) . The findings obtained so far, are relevant to the reactivities of these antibodies on paraffin sections, because carbohydrates rich glycoproteins are usually resistant to various fixatives (Stross et al., 1989) .
As expected, these two antibodies reacted with erythrocytes and endothelial cells, since H antigens are expressed on these cells regardless of the secretor status (Kimmel et al., 1986; Le Pendu et al., 1989) . Similarly, the reactivity of many normal epithelial cells as well as many carcinoma cells of diverse origin, is in agreement with previous studies on the tissue distribution of H and Y antigens (Feizi, 1985; Coon & Weinstein, 1986; Vowden et al., 1986) . Lymphocytes are known to express ABH and Lewis determinants under the control of the Se and Le genes (Dunstan, 1986; Oriol et al., 1980) . However, these antigens are absorbed from the plasma and appear to be primarily of H type 1 (Mollicone et al., 1988; Oriol et al., 1980 (Ray & Blough, 1978) and it has also been recently reported that hapten Y could be expressed by lymphocytes infected with the human immunodeficiency (HIV) virus (Adachi et al., 1988) . However, we did not find staining of lymphocytes in reactive lymph nodes from known HIV-seropositive patients, with BNH9 and BNF13 MoAbs.
Although not expressed on normal lymphocytes, H determinant was previously found to be expressed in B acute lymphoblastic leukaemias (Koller et al., 1987) . Expression of H and/or Y antigens detected by BNH9 MoAb in over 50% of ALC lymphomas is in striking contrast to its rare occurrence in the other lymphoid neoplasms (5.7% of NHL in our cases). As previously demonstrated, the expression of blood group antigens in normal tissues may be dependent on the secretor status, some of these antigens being taken up from the serum, particularly on lymphocytes (Lloyd, 1987; Mollicone et al., 1988; Oriol et al., 1980) . No significant correlation was found with BNH9 staining with either the secretor status or with the blood groups of our patients. In addition, passive absorption from serum was ruled out by the finding, that in the majority of positive cases, the membrane staining was associated with a dot-like staining in the Golgi area. This paranuclear staining pattern is consistent with the fact that glycoproteins and glycolipids are glycoslated in the Golgi apparatus (Alberts et al., 1983) . Lastly, the wide disparity between BNH9 staining in ALC lymphomas and other lymphoid neoplasms, makes the passive absorption phenomenon unlikely. Thus, expression of H and Y antigens may represent biological distinctiveness of ALC lymphomas among NHL. Since these antigens were inducible by stimulation of lymphocytes by mitogens such as PHA or by EBV infection, they are candidates as activation antigens, like other activation markers such as the Ki-I (CD30) antigen (Stein et al., 1985) and the CDw7O antigen (Al Saati et al., 1989a) . However, the reactivity with BNH9 antibody suggests that ALC lymphomas occurring in adults are more heterogeneous than similar tumours in children (41.8 vs 70.7% were respectively positive for BNH9).
In non-lymphoid tumours e.g. urothelial carcinomas, dramatic changes in the expression of blood group antigens such as the loss of ABH and Lea antigens, are usually associated with a more aggressive potential, compared to those in which these antigens are preserved (Coon & Weinstein, 1986; Orntoft et al., 1989) . Preliminary results using univariate analysis suggest that adults with BNH9 positive ALC lymphomas fare worse in comparison to those with BNH9 negative tumours. These findings need to be confirmed by multivariate analysis and controlled prospective studies. No such differences was found in children.
A possible diagnostic use of BNH9 antibody, is in making the distinction between neoplastic cell-rich HD and ALC lymphomas; a problem expected to arise in approximately 10% of cases in our experience. As found in this study, ALC lymphomas, more often than not, show CD30 +, EMA +, BNH9 + phenotype whereas typical Reed-Sternberg cells in HD most frequently co-express CD15 and CD30 antigens (Chittal et al., 1988) . EMA is not expressed by classic ReedStemnberg cells (Chittal et al., 1988) . Similarly, we found the antigens detected by BNH9 antibody to be expressed rarely by Reed-Sternberg cells in HD (Table II) . Even though the differential expression of CD 15 (X-hapten) could further assist in the separation of these entities, caution needs to be exercised, as up to 22% of cases of ALC lymphomas may express the CD15 antigen . The frequent expression of EMA and H and Y antigens by ALC lymphomas indicates that HD and ALC lymphomas may not be as closely related entities as previously suggested on the basis of CD30 expression (Stein et al., 1985) .
The mechanism responsible for expression of H and Y antigens by ALC lymphomas remains to be clarified, but there may be possible explanations. As discussed above, a viral infection could be involved in abnormal glucosyltransferase activity. Alternatively, an abnormality of glycosyltransferase activity may be the result of a specific chromosomal abnormality found in ALC lymphomas. Mason et al. (1990) have demonstrated that ALC lymphomas frequently show a translocation involving exchange of material between chromosomes 2 and 5 at bands 2p23 and 5q35. We found the same translocation in two BNH9-positive ALC lymphomas of our series in which cytogenetic analysis was performed (data not shown). Much further investigation will be needed to clarify this important issue.
